MedTrace Logo

Oral Pregabalin Premedication for Postoperative Pain Relief

NCT04708353 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-09-05

No results posted yet for this study

Summary

Pain management after gynecological surgeries is essential for early mobilization of the patient, decrease postoperative complication and hospital stay. The use of opioids is associated with adverse effects such as nausea, vomiting, ileus, pruritus, sedation and respiratory depression.

Previous studies stated that pregabalin has been used to reduce pre-operative anxiety, acute postoperative pain, postoperative opioid requirements, postoperative nausea, vomiting and postoperative delirium. The most effective dose of pregabalin to relief postoperative pain with least side effect is still under trial.

In this study we will compare between two different doses of pregabalin when given as oral premedication in patients undergoing gynecological surgeries under spinal anesthesia regarding postoperative pain in order to reduce opioids consumption and subsequently avoid opioid-related adverse effects.

Conditions

  • Gynecologic Disease

Interventions

DRUG

placebo capsule (vitamin c)

the patient will receive one placebo capsule (vitamin c) once one hour before the operation

DRUG

Group pregabalin 150

the patient will receive one capsule of pregabalin 150 mg once one hour before the operation

DRUG

Group pregabalin 300

the patient will receive one capsule of pregabalin 300 mg once one hour before the operation

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-20
Primary Completion
2021-10-31
Completion
2021-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04708353 on ClinicalTrials.gov